What changed?
A sourced timeline of research records and material development changes tracked by BACToBasics for MT2 / Melanotan II. Research-publication dates and clinical-development event dates are labeled separately so they are not mistaken for the same type of update.
Tracked items
3
Research sources
2
Development entries
1
Latest recorded date
Verified 2026-09-05
Latest development activity
Verified 2026-09-05 · Phase 1 (historical) · Historical clinical development
Melanotan II was studied in a pilot Phase 1 human program and later small controlled sexual-function studies, but it did not become an FDA-approved tanning or sexual-function medication.
Open source ↗Latest research record by publication date
Published 1998 · Human intervention · Double-blind placebo-controlled crossover study
A small controlled crossover study demonstrated direct human erectogenic effects of Melanotan II.
Open source ↗Tracked timeline
Development changes are dated to the underlying milestone. Research-source entries use the study or source publication year currently stored in the Research Library; that year is not presented as the date BACToBasics added the record.
Phase 1 (historical) · Historical clinical development
Melanotan II was studied in a pilot Phase 1 human program and later small controlled sexual-function studies, but it did not become an FDA-approved tanning or sexual-function medication.
Human intervention · Double-blind placebo-controlled crossover study
A small controlled crossover study demonstrated direct human erectogenic effects of Melanotan II.
Human intervention · Phase 1 human study
This early Phase 1 study provides direct human exposure evidence for Melanotan II and documented melanocortin-related effects and adverse events.
Following a compound creates a clean baseline from the updates currently known. When BACToBasics later records a new research source or material development change, the My Tools update badge can surface it as new for you.
BACToBasics provides educational research organization only. A development milestone does not predict future approval, and a research record does not establish that a compound is safe, effective, approved, or appropriate for use.